Laura Mungapen

The economic impact of overactive bladder syndrome in six Western countries

Debra E. Irwin, Laura Mungapen, Ian Milsom et al. · British Journal of Urology · 2008 · 220 citations

Medicine, Pharmacoeconomics, Urology +17

Cost-utility analysis of indacaterol in Germany: A once-daily maintenance bronchodilator for patients with COPD

David Price, Alastair Gray, Rupert Gale et al. · Respiratory Medicine · 2011 · 38 citations · Full text

Medicine, Internal Medicine, Pharmacoeconomics +13

Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling

Yumi Asukai, Michael Baldwin, Tiago A. H. Fonseca et al. · PharmacoEconomics · 2013 · 24 citations · Full text

Medicine, Pharmacoeconomics, Clinical Epidemiology +16

Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching

Jesper Jørgensen, Laura Mungapen, Panos Kefalas · Journal of Market Access & Health Policy · 2019 · 19 citations · Full text

Pharmacy, Pharmacoeconomics, Gene Therapy +15

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

Panos Kefalas, Jesper Jørgensen, N. Merryfield et al. · Journal of Market Access & Health Policy · 2018 · 18 citations · Full text

Public Affairs, Health Policy, Oncology +17